Business Context and Reporting Period
This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on May 23, 2024, with the earliest event reported on the same date. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change is the appointment of Jean-Jacques Bienaimé as a Class III director, effective June 1, 2024. His term expires at the 2026 annual meeting of stockholders. Additionally, Mr. Bienaimé was appointed to the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Compensation Details
There is no guidance, outlook, or management commentary regarding business operations or risks in this filing. The document details the following compensatory arrangements for the new director:
- Initial Stock Option: Grant to purchase 20,000 shares of common stock at the closing price on the grant date, vesting in equal quarterly installments over three years.
- Annual Stock Option: Eligibility for an annual grant to purchase 10,000 shares in connection with the annual meeting of stockholders.
- Cash Retainer: $40,000 annual cash retainer for Board service.
- Committee Retainer: Additional $5,000 annual retainer for service on the Nominating Committee.
- Indemnification: The Company will enter into a standard indemnification agreement covering expenses, damages, and settlements arising from his service.
Investor Verification Checklist
- Verify the effective date of the director appointment (June 1, 2024) against the company's official governance calendar.
- Confirm the exercise price of the initial 20,000 share option grant once the grant date is finalized.
- Review the updated composition of the Audit, Compensation, and Nominating Committees as listed in the filing.
- Check for any subsequent filings regarding the execution of the indemnification agreement.